Advertisement

Topics

IPO to Fuel Denali’s Drugs for Alzheimer’s, Other Brain Diseases

20:53 EST 13 Nov 2017 | Xconomy

One of biotech’s richest private companies, Denali Therapeutics, has set its sights on an IPO to push ahead with treatments for Alzheimer’s and other confounding brain diseases. The filing marks $100 million as its IPO target, but market conditions often shift a company’s sights in the run-up to a debut. Denali’s disclosure comes on the […]

Original Article: IPO to Fuel Denali’s Drugs for Alzheimer’s, Other Brain Diseases

NEXT ARTICLE

More From BioPortfolio on "IPO to Fuel Denali’s Drugs for Alzheimer’s, Other Brain Diseases"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Psychiatry
Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...